Cullinan Therapeutics, Inc. reported total assets of $322.6 million as of September 30, 2026, a decrease from $448.4 million at the end of 2025, primarily driven by a reduction in short-term and long-term investments. The company maintains a strong liquidity position with $289.6 million in cash, cash equivalents, and short-term investments to fund its clinical-stage product candidates. Total liabilities remained relatively stable at $41.3 million.
Cullinan Therapeutics reported third quarter 2026 financial results and provided a corporate update on its T cell engager portfolio. The company ended the quarter with $313.8 million in cash and investments, providing a projected cash runway into 2029. Key upcoming milestones include data readouts for CLN-978 in autoimmune indications and the completion of the zipalertinib NDA submission in November.
Term
Q3 2026
“Our progress this quarter underscores our ability to execute across a differentiated and rapidly advancing portfolio. In addition to the recent clinical success and regulatory progress of zipalertinib, we have advanced velinotamig into a global study in autoimmune cytopenias and initiated a potentially registrational Phase 2 study of CLN-049 in relapsed and refractory AML.”
Nadim Ahmed, President and CEO of Cullinan Therapeutics
“Looking ahead, we remain focused on strengthening our leadership position in the T cell engager space. This December, we will share an update for CLN-978 across our ongoing clinical trials in three autoimmune indications and will share updated data for CLN-049 at the ASH Annual Meeting. With multiple upcoming clinical catalysts and regulatory milestones, coupled with our strong balance sheet, we are well positioned to translate this momentum into meaningful progress for patients and long-term value for shareholders.”
Nadim Ahmed, President and CEO of Cullinan Therapeutics